Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease
Doss JF, Jonassaint JC, Garrett ME, Ashley-Koch AE, Telen MJ, Chi JT
PloS one · 55 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo clínico controlado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Doris Duke Charitable Foundation
- Subvenciones
- Doris Duke Charitable Foundation (2011098)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2016-04-12 · PLoS One · vol. 11 · número 4 · pág. e0152895
- Editorial
- Public Library of Science
- Citado
- 67 citas · más que el 96% de estudios similares · 4.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 47 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · Quinazolinone synthesis and applications · Synthesis and Characterization of Heterocyclic Compounds
- Palabras clave
- Sulforaphane, Glucoraphanin, Brassica, Chemistry, Food science, Biochemistry, Biology, Botany, Glucosinolate
- MeSH
- cells, cultured, humans, brassica, anemia, sickle cell, isothiocyanates, sulfoxides, rna, messenger, oxidative stress, adult, middle aged, female, male, nf-e2-related factor 2, heme oxygenase-1
6 autores
- Jennifer F. Doss🇺🇸Duke University
- Jude Jonassaint🇺🇸Duke University
- Melanie E. Garrett🇺🇸Duke University
- Allison E. Ashley‐Koch🇺🇸Duke University
- Marilyn J. Telen🇺🇸 · autor de correspondenciaDuke University
- Jen‐Tsan Chi🇺🇸 · autor de correspondenciaDuke University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Sickle cell disease (SCD) is the most common inherited hemoglobinopathy worldwide. Our previous results indicate that the reduced oxidative stress capacity of sickle erythrocytes may be caused by decreased expression of NRF2 (Nuclear factor (erythroid-derived 2)-like 2), an oxidative stress regulator. We found that activation of NRF2 with sulforaphane (SFN) in erythroid progenitors significantly increased the expression of NRF2 targets HMOX1, NQO1, and HBG1 (subunit of fetal hemoglobin) in a dose-dependent manner. Therefore, we hypothesized that NRF2 activation with SFN may offer therapeutic benefits for SCD patients by restoring oxidative capacity and increasing fetal hemoglobin concentration. To test this hypothesis, we performed a Phase 1, open-label, dose-escalation study of SFN, contained in a broccoli sprout homogenate (BSH) that naturally contains SFN, in adults with SCD. The primary and secondary study endpoints were safety and physiological response to NRF2 activation, respectively. We found that BSH was well tolerated, and the few adverse events that occurred during the trial were not likely related to BSH consumption. We observed an increase in the mean relative whole blood mRNA levels for the NRF2 target HMOX1 (p = 0.02) on the last day of BSH treatment, compared to pre-treatment. We also observed a trend toward increased mean relative mRNA levels of the NRF2 target HBG1 (p = 0.10) from baseline to end of treatment, but without significant changes in HbF protein. We conclude that BSH, in the provided doses, is safe in stable SCD patients and may induce changes in gene expression levels. We therefore propose investigation of more potent NRF2 inducers, which may elicit more robust physiological changes and offer clinical benefits to SCD patients. Trial registration: ClinicalTrials.gov NCT01715480.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.